Janssen Finally Adds Warning for Maculopathy to IC (interstitial cystitis) Drug Elmiron
July 23, 2020
Previous Post Next Post

Elmiron® Manufacturer Affirms Link to Degenerative Eye Disorder

For over two decades, Janssen Pharmaceuticals has manufactured and sold a bladder drug called Elmiron®, which is currently the only drug approved to treat IC (interstitial cystitis). However, after multiple peer-reviewed studies showed a link between Elmiron and maculopathy, serious and degenerative eye disorder, Janssen officially added a warning label to the drug on June 2, 2020.

Although Janssen previously acknowledged that Elmiron could potentially result in “optic neuritis” in rare circumstances, the medical community has expressed concern that the risk of developing maculopathy is significantly greater and far from rare. Maculopathy is an eye disorder that affects pigment in the retina. With long-term Elmiron use, this condition can lead to permanent vision loss and other lasting consequences for patients.

Long-term effects associated with using Elmiron :

  • Spots and visual obstructions in the subject’s field of vision
  • Increasing eye strain during everyday activities
  • Blurred and dimmed vision
  • Difficulty adjusting to light or darkness
  • Gradual vision loss and blindness

On June 16, 2020, the Food & Drug Administration (FDA) released the new warning label to the public. According to the release, all patients must now be informed about the risk of vision loss and blindness, especially if there is a family or personal medical history of ophthalmologic conditions.


What Can I Do If I’m Affected by Pigmentary Maculopathy?

As of 2020, the only company approved to manufacture and sell Elmiron is Janssen, a subsidiary of Johnson & Johnson.

If you or a loved one suffered vision loss, blindness, or other symptoms of Maculopathy after taking Elmiron, contact Ashcraft & Gerel for a free legal consultation today.

At Ashcraft & Gerel, we have recovered over $1 billion for injury victims and can bring decades of experience with complex pharmaceutical litigation to your Elmiron case. It is our goal to hold companies like Janssen accountable when they fail to protect the public from preventable drug injuries. When you contact our team, we will help you understand your legal options.

Contact us at (866) 709-0505 or submit our online form to schedule a free consultation.